← All organizations
Fortress Biotech
For profitContributed to NME
Also known as: Avenue Therapeutics, Inc. | Caelum Biosciences | Checkpoint Therapeutics, Inc. | CHECKPOINT THERAPEUTICS INC | Coronado Biosciences, Inc. | Cyprium Therapeutics, Inc. | Helocyte | JOURNEY | Journey Medical Corp | Journey Medical Corporation | Mustang Bio | Mustang Bio, Inc.
Highest phase reached
Phase 3
First clinical trial
Nov 1, 2011First marketed drug
Jun 1, 2006First NDA
Dec 13, 2024Last known activity
Dec 13, 2024
Timeline
1980s
- Aug 30, 1985
sulconazole— NDA Secondary Org
2000s
- Jun 1, 2006
Fortress Biotech— Founded
2010s
- Feb 18, 2015
Revogenex, Inc.— Acquired
2020s
- Dec 13, 2024
cosibelimab— Marketing Organization
- Dec 13, 2024
cosibelimab— NDA Organization
Drugs by trial phase (28 distinct, 28 trials)
Phase 3 (13 own, 0 via acquisition)
Phase 2 (10 own, 1 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Amyloidosis
- Autism Spectrum Disorder
- Autistic Disorder
- Carcinoma
- Carcinoma, Merkel Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell
- Colitis
- Colitis, Ulcerative
- Crohn Disease
- Cytomegalovirus Infections
- Endometrial Neoplasms
- Glioblastoma
- Glioma
- Immunoglobulin Light-chain Amyloidosis
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid, Chronic-Phase
- Lung Diseases
- Lung Neoplasms
- Lymphadenopathy
- Lymphoma
- Mesothelioma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms
- Paraproteinemias
- Postoperative Pain
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Psoriasis
- Ulcer
Marketed drugs (5)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (33)
- NCT04074512Lead sponsorN/A—
- NCT05597462Study directorPhase 1Sep 30, 2022
- NCT05597462Lead sponsorPhase 1Sep 30, 2022
- NCT05360238Lead sponsorPhase 1/Phase 2May 24, 2022
- NCT05452785Lead sponsorPhase 1May 7, 2022
- NCT05452785Study directorPhase 1May 7, 2022
- NCT05343455Lead sponsorPhase 3Mar 29, 2022
- NCT05343455Study directorPhase 3Mar 29, 2022
- NCT05296629Lead sponsorPhase 3Mar 14, 2022
- NCT05296629Study directorPhase 3Mar 14, 2022
- NCT04786964Lead sponsorPhase 3Sep 30, 2021
- NCT04512235Lead sponsorPhase 3Aug 25, 2020
- NCT04504825Lead sponsorPhase 3Aug 25, 2020
- NCT04304144Lead sponsorPhase 2Mar 18, 2020
- NCT04109482Lead sponsorPhase 1/Phase 2Oct 16, 2019
Details
- Founded
- Seattle, WA, US Jun 1, 2006
- First NDA
- Dec 13, 2024
- Last known activity
- Dec 13, 2024